Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Vyvgart

UBS Just Upgraded Argenx Stock. Here's Why.

Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.

Barchart · Aug 26

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

MarketBeat · Jun 5

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ:ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga · Aug 26, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Benzinga · May 24, 2022

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Argenx SE's (NASDAQ:ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated. A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo…

Benzinga · May 5, 2022

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores

Argenx SE (NASDAQ: ARGX) announced

Benzinga · Apr 5, 2022

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has

Benzinga · Mar 22, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

biotechnology

291 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United States

423,861 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.